[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650243":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":32,"responsibleParty":47,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":32,"enrollmentInfo":64,"targetDuration":32,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":75,"whyStopped":32,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":32},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"TEER+Ablation","EXPERIMENTAL","Patients will undergo catheter ablation and transcatheter edge to edge repair.",[13,14],"Device: Transcatheter edge to edge repair","Procedure: Catheter ablation",{"label":16,"type":17,"description":18,"interventionNames":19},"Catheter ablation","ACTIVE_COMPARATOR","Patients will undergo catheter ablation only.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Transcatheter edge to edge repair","Participants will undergo catheter ablation for persistent atrial fibrillation followed by transcatheter edge-to-edge repair (TEER) for the treatment of functional mitral regurgitation during the same hospitalization. TEER will be performed using an approved transcatheter mitral valve repair system to reduce mitral regurgitation severity and improve cardiac function.",[9],[27],"TEER",{"type":29,"name":16,"description":30,"armGroupLabels":31,"otherNames":32},"PROCEDURE","Participants will undergo catheter ablation for persistent atrial fibrillation during the study period. The procedure will include pulmonary vein isolation with additional ablation strategies as clinically indicated.",[16,9],null,[34],{"name":35,"affiliation":5,"role":36},"Mao Chen","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Zhengang Zhao","CONTACT","86-18980733914","zhaozhengang@foxmail.com",{"name":44,"role":40,"phone":45,"phoneExt":32,"email":46},"Lijun Zeng","86-18810672833","zenglijun2019@gmail.com",{"type":48,"investigatorFullName":35,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","Director of Department of Cardiology",[51],{"name":52,"class":53},"Abbott","INDUSTRY","100650243","ablation-with-transcatheter-edge-to-edge-repair-for-atrial-functional-mitral-regurgitation-and-atrial-fibrillation-100650243",false,"NCT07744035","Ablation With Transcatheter Edge-to-edge Repair for Atrial Functional Mitral Regurgitation and Atrial Fibrillation","Ablation wiTh TRAnsCatheter Edge-to-edge Repair Versus ablaTION Alone for Atrial Functional Mitral Regurgitation and Atrial Fibrillation (ATTRACTION Study)","ATTRACTION","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Left ventricular ejection fraction ≥ 50%\n* Grading of MR: 3+ or 4+ (effective regurgitant orifice area≥30mm2, regurgitant volume ≥45ml)\n* Valve morphology: MR originating from the mid portion of the valve; mitral valve area\\> 4 cm2; Length of posterior leaflet ≥10 mm; Sufficient leaflet tissue for mechanical coaptation: coaptation depth\\\u003C 11 mm, coaptation length\\> 2 mm\n* Rate control in suspected AF-induced cardiomyopathy (heart rate \\\u003C80 bpm at rest and \\\u003C110 bpm during exercise)\n* Patients must be willing to comply with all follow-up requirements\n\nExclusion Criteria:\n\n* Life expectancy\\\u003C 1 year due to non-cardiac conditions\n* Primary mitral regurgitation: valve abnormalities including leaflet tethering from LV dysfunction, intrinsic leaflet pathology (prolapse, flail, calcification, severe thickening), mitral annular calcification (either severe or \\\u003Csevere but extending into the leaflets), and\u002For any mixed pathology\n* Active endocarditis of the mitral valve or rheumatic mitral valve disease\n* Hypotension (systolic pressure \\\u003C 90 mmHg) or requirement for inotropic support or mechanical hemodynamic support\n* Severe tricuspid regurgitation; Physical evidence of right-sided congestive heart failure with echocardiographic evidence of severe right ventricular dysfunction; Fixed pulmonary artery systolic pressure\\> 70 mmHg\n* Stroke\u002FTIA, TAVR, CRT\u002F CRT-D\u002F ICD, cardiac intervention or surgery within 30 days before randomization\n* Any prior MV surgery or transcatheter procedure\n* Need for any cardiac surgery (other than for MV disease)\n* Untreated clinically significant coronary artery disease\n* Echocardiographic evidence of intracardiac thrombus\n* Active infections requiring current antibiotic therapy\n* Patients who cannot tolerate anti-platelet\u002Fanticoagulation agents\u002Fcontrast media\n* Pregnancy\n* Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with medical therapy) and follow-up visits\n* Patient (or legal guardian) unable or unwilling to provide written informed consent before study enrollment","ALL","18 Years",{"count":65,"type":66},384,"ESTIMATED","INTERVENTIONAL",[69],"NA","This trial is a randomized study for patients with significant atrial functional mitral regurgitation (AFMR) and atrial fibrillation (AF). The composite endpoint of all-cause mortality, cardiovascular-related hospitalizations, AF recurrence, and quality of life improvement is hypothesized to be superior with the combination of transcatheter edge-to-edge repair (TEER) and catheter ablation, compared with catheter ablation alone.",[72,73],"Atrial Functional Mitral Regurgitation","Atrial Fibrillation (AF)",[23,16],"NOT_YET_RECRUITING","2026-08-02",{"date":78,"type":79},"2026-08-04","ACTUAL",{"date":81,"type":66},"2026-09-01",{"date":83,"type":66},"2029-09-01",{"name":35,"class":6}]